Wu et al. developed a B7-H6-specific BiTE to enhance cancer elimination and host anticancer immunity and found that it increased the survival of RMA/B7-H6 lymphoma-bearing mice through perforin and IFN-r effector mechanisms [81]. This evidence concerns the gene NCR3LG1 and lymphoma.